2869056-74-4
Chemical Structure
Bilpatide
Synonym(s): RAY1225
- CAS No.: 2869056-74-4
- Formula:C229H351N49O71
- Molecular Weight:4926.52
SMILES: O=C(NC(C)(C)C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(NC(C)(C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCNC(CN(C(COCCOCCNC(COCCOCCNC(CC[C@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)C3)=O)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCNC3=O)C(N[C@@H](C)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC5=CNC6=CC=CC=C56)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(NCC(NCC(N7[C@@H](CCC7)C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@@H](C)C(N8[C@@H](CCC8)C(N9[C@@H](CCC9)C(N%10[C@@H](CCC%10)C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC%11=CC=C(C=C%11)O)N
Biological Activity: Bilpatide (RAY1225) is a dual GIP/GLP-1 receptor agonist. Bilpatide has higher affinity for the GIP receptor than for the GLP-1 receptor. Bilpatide reduces HbA1c levels. Bilpatide can be used in research on obesity and type 2 diabetes[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bilpatide | Bilpatide (RAY1225) is a dual GIP/GLP-1 receptor agonist. Bilpatide has higher affinity for the GIP receptor than for the GLP-1 receptor. Bilpatide reduces HbA1c levels. Bilpatide can be used in research on obesity and type 2 diabetes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
-
[1]. WHO Drug Information Vol. 40, No. 2, 2026.
- [2]. Ji L, et al. Efficacy and Safety of Bilpatide, a Bi-weekly GIP/GLP-1 Receptor Agonist, in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial[J]. 2026.
- [3]. Ji L, et al. 795-P: Efficacy and Safety of RAY1225 Once Every Two Weeks in Chinese Adults with Type 2 Diabetes (SHINING-1)[J]. Diabetes, 2025, 74(Supplement_1): 795-P.
